161 related articles for article (PubMed ID: 33045146)
21. Copy number variations identified in thyroid FNA specimens are associated with Hürthle cell cytomorphology.
Abi-Raad R; Prasad ML; Adeniran AJ; Cai G
Cancer Cytopathol; 2022 Jun; 130(6):415-422. PubMed ID: 35332982
[TBL] [Abstract][Full Text] [Related]
22. Sonographically suspicious thyroid nodules with initially benign cytologic results: the role of a core needle biopsy.
Ha EJ; Baek JH; Lee JH; Song DE; Kim JK; Shong YK; Hong SJ
Thyroid; 2013 Jun; 23(6):703-8. PubMed ID: 23544697
[TBL] [Abstract][Full Text] [Related]
23. Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms.
Troncone G; Volante M; Iaccarino A; Zeppa P; Cozzolino I; Malapelle U; Palmieri EA; Conzo G; Papotti M; Palombini L
Cancer; 2009 Dec; 117(6):522-9. PubMed ID: 19787802
[TBL] [Abstract][Full Text] [Related]
24. Use of a thin-layer technique in thyroid fine needle aspiration.
Malle D; Valeri RM; Pazaitou-Panajiotou K; Kiziridou A; Vainas I; Destouni C
Acta Cytol; 2006; 50(1):23-7. PubMed ID: 16514836
[TBL] [Abstract][Full Text] [Related]
25. Assessment of malignancy rate in thyroid nodules according to the Bethesda system of fine-needle aspiration. Report from a tertiary center in the Southwestern region of Saudi Arabia.
Al-Shraim MM; Kaood OM; Hussein MR; Al-Ahmary AM; Al Shehri GY; Jastania RA; Mahfouz AA; Abu-Eshy SA
Saudi Med J; 2012 Feb; 33(2):167-71. PubMed ID: 22327757
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors of malignancy in patients with cytologically suspicious for Hurthle cell neoplasm of thyroid nodules.
Lee KH; Shin JH; Ko ES; Hahn SY; Kim JS; Kim JH; Oh YL
Int J Surg; 2013; 11(9):898-902. PubMed ID: 23916366
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial DNA "common deletion" in post-fine needle aspiration infarcted oncocytic thyroid tumors.
Conti L; Vatrano S; Bertero L; Masu L; Pacchioni D; Daniele L; De Rosa G; Cassoni P; Volante M; Papotti M
Hum Pathol; 2017 Nov; 69():23-30. PubMed ID: 28962946
[TBL] [Abstract][Full Text] [Related]
28. Papillary Hürthle cell tumor of thyroid: report of a case with a cytomorphologic approach to diagnosis.
Dziecioł J; Musiatowicz B; Zimnoch L; Kemona A; Sulkowski S
Acta Cytol; 1996; 40(2):311-4. PubMed ID: 8629418
[TBL] [Abstract][Full Text] [Related]
29. RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation.
Gilani SM; Abi-Raad R; Garritano J; Cai G; Prasad ML; Adeniran AJ
Cancer Cytopathol; 2022 Apr; 130(4):284-293. PubMed ID: 34847284
[TBL] [Abstract][Full Text] [Related]
30. Hürthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology.
Yazgan A; Balci S; Dincer N; Kiyak G; Tuzun D; Ersoy R; Cakir B; Guler G
Cytopathology; 2014 Jun; 25(3):185-9. PubMed ID: 24024935
[TBL] [Abstract][Full Text] [Related]
31. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
32. Hurthle cells in fine needle aspiration cytology of the thyroid: a potential diagnostic dilemma?
Wong YP; Md Isa N; Md Zin RR; Noor Akmal S
Malays J Pathol; 2015 Apr; 37(1):49-52. PubMed ID: 25890614
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of fine needle aspiration cytology in thyroid lesions.
Sinna EA; Ezzat N
J Egypt Natl Canc Inst; 2012 Jun; 24(2):63-70. PubMed ID: 23582597
[TBL] [Abstract][Full Text] [Related]
34. Surgeon-performed ultrasound predictors of malignancy in patients with Hürthle cell neoplasms of the thyroid.
Parikh PP; Allan BJ; Lew JI
J Surg Res; 2013 Sep; 184(1):247-52. PubMed ID: 23535112
[TBL] [Abstract][Full Text] [Related]
35. 'Indeterminate for malignancy' (Tir3/Thy3 in the Italian and British systems for classification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact.
Pagni F; Prada M; Goffredo P; Isimbaldi G; Crippa S; Di Bella C; Leone BE;
Cytopathology; 2014 Jun; 25(3):170-6. PubMed ID: 23937572
[TBL] [Abstract][Full Text] [Related]
36. Cytology of Hürthle cell neoplasms of thyroid gland.
Hemachandran M; Rajwanshi A; Srinivasan R; Nijhawan R; Radotra BD
Indian J Pathol Microbiol; 2007 Oct; 50(4):859-61. PubMed ID: 18306589
[TBL] [Abstract][Full Text] [Related]
37. How "suspicious" is that nodule? Review of "suspicious" Afirma gene expression classifier in high risk thyroid nodules.
Roychoudhury S; Klein M; Souza F; Gimenez C; Laser A; Shaheen Cocker R; Chau K; Das K
Diagn Cytopathol; 2017 Apr; 45(4):308-311. PubMed ID: 28188700
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Diagnosis of Neoplastic or Malignant Hürthle Cell Lesions: A Chimera?
Díaz Del Arco C; Fernández Aceñero MJ
Acta Cytol; 2018; 62(3):193-203. PubMed ID: 29723867
[TBL] [Abstract][Full Text] [Related]
39. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
40. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
